What is Nudge?
Founded in 2024, Nudge is at the forefront of developing vertically integrated devices that utilize non-invasive, focused ultrasound technology to safely stimulate deep brain regions without the need for surgery. The company's innovative approach combines advanced imaging, simulation, and custom hardware to enable precise, targeted brain stimulation. Nudge's initial efforts are directed towards addressing neurological and mental health conditions, including chronic pain, addiction, and anxiety, positioning it as a key player in the burgeoning field of neurotechnology.
How much funding has Nudge raised?
Nudge has raised a total of $100M across 1 funding round:
Series A
$100M
Series A (2025): $100M with participation from Greenoaks and Thrive Capital
Key Investors in Nudge
Greenoaks
Greenoaks is a venture capital firm dedicated to identifying and partnering with exceptional early-stage companies, aiming to support focused teams throughout their growth and foster innovation.
Thrive Capital
Thrive Capital is an investment venture capital company based in New York, primarily focusing on internet and software investments.
What's next for Nudge?
With its recent major strategic investment, Nudge is poised to accelerate its research and development efforts, potentially scaling its operations and expanding its clinical trials. This substantial backing suggests a strong market validation for its non-invasive brain stimulation technology and its potential to revolutionize treatment for a range of neurological and mental health disorders. The company's focus on combining sophisticated imaging with custom hardware indicates a commitment to precision and safety, which will be critical as it moves towards broader market adoption and therapeutic application.
See full Nudge company page
